Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SRF114 |
Trade Name | |
Synonyms | SRF-114|SRF 114|CHS-114|CHS114|CHS 114 |
Drug Descriptions |
SRF114 is a monoclonal antibody that targets CCR8, which potentially induces antibody-dependent cellular cytotoxicity against CCR8-expressing T-regulatory cells and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2020;8; Journal for ImmunoTherapy of Cancer 2022;10). |
DrugClasses | CCR8 Antibody 10 |
CAS Registry Number | NA |
NCIT ID | C198695 |